Safety profile of fluvastatin
1Department of Clinical Research and Development, Sandoz Pharma Ltd, Basel, Switzerland.
British Journal of Clinical Practice. Supplement
|January 1, 1996
Summary
Fluvastatin, a statin drug, demonstrates good tolerability and safety in patients with hyperlipidemia. Adverse events are infrequent and comparable to placebo, with no increased risk of myopathy or rhabdomyolysis.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
Background:
- Statins are widely used lipid-modifying agents known for good tolerability.
- Older lipid-lowering drugs often have poor patient compliance.
- Fluvastatin is a newer statin evaluated in numerous hyperlipidemia patients.
Purpose of the Study:
- To assess the safety and tolerability profile of fluvastatin.
- To compare fluvastatin's adverse event incidence with placebo and other lipid-modifying agents.
Main Methods:
- Controlled clinical studies involving patients with hyperlipidemia.
- Evaluation of adverse events, including gastrointestinal disturbances, liver enzyme elevations, and creatine kinase levels.
- Assessment of myopathy, rhabdomyolysis, and drug interactions.
Main Results:
- Most adverse events with fluvastatin were not higher than placebo.
- Gastrointestinal disturbances were common to all statins but less frequent than with cholestyramine or fibrates.
- Liver transaminase elevations and creatine kinase elevations led to discontinuation at rates similar to placebo.
- No drug-related myopathy or rhabdomyolysis were reported; myalgia incidence was similar to placebo.
- Fluvastatin did not interfere with antihypertensive efficacy.
- Overall discontinuation rates due to adverse events were comparable to placebo.
Conclusions:
- Fluvastatin exhibits a favorable safety profile, comparable to placebo.
- It is well-tolerated in patients with hyperlipidemia, with a low incidence of significant adverse events.
- Fluvastatin offers a safe and effective option for lipid modification.
More Related Videos
Related Concept Videos
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...